TY - JOUR
T1 - Efficacy and safety of nivolumab in patients with non-small cell lung cancer
T2 - a retrospective study in clinical practice
AU - Montana, Marc
AU - Garcia, Marie Eve
AU - Ausias, Nathalie
AU - Jeanpierre, Marion
AU - Meiffren, Margaux
AU - Giorgi, Roch
AU - Vanelle, Patrice
AU - Barlesi, Fabrice
N1 - Publisher Copyright:
© 2018, © 2018 Edizioni Scientifi che per l’Informazione su Farmaci e Terapia.
PY - 2019/2/17
Y1 - 2019/2/17
N2 - Nivolumab, a fully human immunoglobulin monoclonal antibody inhibiting the programmed cell death protein‐1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. The aim of the present study was to investigate the efficacy and safety of nivolumab for pretreated patients with non-small cell lung cancers in clinical practice. In this observational monocentric retrospective study, 98 patients were enrolled between February 2015 and February 2016. The global median overall survival was 6.34 months (95% confidence interval (CI) : 4.11–10.88) and the global median progression free survival was 1.84 months (95% CI: 1.68–2.73). In the univariate analysis, clinical performance status score was the only factor significantly correlated with overall survival. The safety profile of nivolumab is consistent with that described in prior studies, with only 7% undesirable effects requiring the discontinuation of treatment. The results of the present study demonstrate that nivolumab affords clinical efficacy and manageable tolerability in patients with non-small cell lung cancers.
AB - Nivolumab, a fully human immunoglobulin monoclonal antibody inhibiting the programmed cell death protein‐1 receptor, demonstrated robust efficacy and a manageable safety profile across multiple tumor types in clinical trials. The aim of the present study was to investigate the efficacy and safety of nivolumab for pretreated patients with non-small cell lung cancers in clinical practice. In this observational monocentric retrospective study, 98 patients were enrolled between February 2015 and February 2016. The global median overall survival was 6.34 months (95% confidence interval (CI) : 4.11–10.88) and the global median progression free survival was 1.84 months (95% CI: 1.68–2.73). In the univariate analysis, clinical performance status score was the only factor significantly correlated with overall survival. The safety profile of nivolumab is consistent with that described in prior studies, with only 7% undesirable effects requiring the discontinuation of treatment. The results of the present study demonstrate that nivolumab affords clinical efficacy and manageable tolerability in patients with non-small cell lung cancers.
KW - Anti-PD1
KW - ECOG performance status
KW - Nivolumab
KW - immunotherapy
KW - non-small cell lung cancer
KW - real life
UR - http://www.scopus.com/inward/record.url?scp=85059447571&partnerID=8YFLogxK
U2 - 10.1080/1120009X.2018.1551753
DO - 10.1080/1120009X.2018.1551753
M3 - Article
C2 - 30595104
AN - SCOPUS:85059447571
SN - 1120-009X
VL - 31
SP - 90
EP - 94
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - 2
ER -